BeOne Medicines Presents Updated Phase 3 Data for BRUKINSA at EHA

BeOne Medicines (ONC) presented updated Phase 3 clinical data on its BTK inhibitor, BRUKINSA, showing a significant improvement in progression-free survival compared to standard treatment. The results reinforce the drug's effectiveness and safety profile over long-term use.

By Abdul Rahman Sat, June 20, 2026 at 9:47 PM GMT+3 1 min read · Yahoo Finance · June 20, 2026, 18:47 UTC

BeOne Medicines Presents Updated Phase 3 Data for BRUKINSA at EHA

Tickers: $ONC

Topics: BRUKINSA BTK inhibitor chronic lymphocytic leukemia Phase 3 data

Read the full article at Yahoo Finance

More World news

Archer Aviation Enters Multi-Year Partnership with Formula One Seeking Alpha · November 12, 2026, 14:16 UTC
Edgewell Personal Care Announces Quarterly Dividend of $0.15 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Hudbay Minerals Announces Quarterly Dividend of CAD 0.01 Per Share Seeking Alpha · November 12, 2026, 14:16 UTC
Warby Parker Unveils AI-Powered Intelligent Eyewear Collection in Partnership with Google and Samsung Seeking Alpha · November 12, 2026, 14:17 UTC
Where Food Comes From Reports Q3 Revenue Growth and Improved Gross Margins Seeking Alpha · November 12, 2026, 14:17 UTC
Medical Care Technologies Inc. Reports Q3 Revenue Growth and Significant Net Income Increase Seeking Alpha · November 12, 2026, 14:17 UTC
Digi International Reports Record Fiscal 2026 Results and Announces Acquisition of Disruptive Technologies Motley Fool · November 12, 2026, 14:15 UTC
U.S. Trade Representative Jamieson Greer to Discuss Tariff Policies and Export Controls CNBC · November 12, 2026, 13:31 UTC
Coinbase CEO Brian Armstrong Discusses Binance Hack and Political Shifts Impacting Crypto CNBC · November 12, 2026, 13:44 UTC
Tradeify Announces Multi-Year Partnership with Inter Miami CF PR Newswire · November 12, 2026, 14:15 UTC